德琪医药塞利尼索15项研究及成果将在2021 ASCO公布

本文插图

上海和香港2021年6月2日 /美通社/ -- 致力于研发和商业化创新肿瘤疗法的领先生物制药公司——德琪医药有限公司（简称“德琪医药” ，香港联交所股票代码：6996.HK）今日宣布，同类首款选择性核输出抑制剂——塞利尼索（selinexor）15项研究及成果将在2021年美国临床肿瘤学大会（ASCO）年会上公布。此届 ASCO 会议于6月4日至6月8日在线上召开。
线上摘要
Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).
摘要编号：8027
Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone(Vd) in patients with previously treated multiple myeloma.
摘要编号：8024
Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.
摘要编号：8019
Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.
摘要编号：e19037
Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dosedexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).
摘要编号：e20002
Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).
摘要编号：8018
SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.
摘要编号：TPS5610
Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.
摘要编号：e15579
A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
摘要编号：TPS2071
A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.
摘要编号：11534
Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.
摘要编号：5565
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
【德琪医药塞利尼索15项研究及成果将在2021 ASCO公布】摘要编号：8038
A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.